Skip to main content

Science
Products
Stories
Newsroom
About

Investors Media Careers Partners

Careers
Investors

Changed

Changed

How can we help you?

26 search results for igg

filterselect all | reset

Sort by

Order

Suggestions within Pfizer.com

Announcement

Article

Page

People Profiles

Podcast

Press Release

Product

filter select all | reset

Type

Announcement

Article

Page

People Profiles

Podcast

Press Release

Product

Date Range

Maternal Immunization

molecules called immunoglobulin G, or IgG, through the placenta to her …

Page
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

or showed a ≥four-fold increase in IgG titers compared to baseline if …

Press Release
Study Shows Prevenar 13* Is Immunogenic In Young Children Previously Vaccinated With Prevenar*

The study measured immunoglobulin G (IgG) and response was assessed as …

Press Release
Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants

serotype-specific immunoglobin G (IgG) concentrations after Dose 3 and NI of IgG geometric mean concentrations …

Press Release
Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate

to estimate anti-CPS immunoglobulin (IgG) antibody concentrations in infant Naturally acquired anti-CPS IgG concentrations correlated with …

Press Release
Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate

Mean Fold Rise) in anti-OspA IgG antibody titers compared with seroconverted to anti-OspA IgG after the booster dose, meaning …

Press Release
Valneva Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15

Immunogenicity, measured by observing IgG antibodies2 against the six most Immunoglobulin G antibodies (IgG) are found in all body fluids. …

Press Release
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2

significantly elevated RBD-binding IgG antibodies with geometric mean as measured by RBD-binding IgG concentrations and SARS-CoV-2 …

Press Release
Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020

with prespecified serotype-specific IgG concentrations and IgG Geometric Means Concentrations …

Press Release
Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union

objective of immunoglobulin G (IgG) geometric mean concentrations For the NI co-primary objective of IgG GMCs one month after Dose 2, 16 of …

Press Release

Current page 1
Page 2
Page 3

Home
News
Press Releases

Press Release Archive

Press Releases

Year

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

Month

January

February

March

April

May

June

July

August

September

October

November

December

View 12

View 24

View 48

Categories

Corporate
Financial
Prescription Medicines
Research and Pipeline
Social Responsibility
Vaccines

Keywords

All Keywords

Covid-19
Finance
Investments
Leadership
Medicines
Partnerships
Research
Responsibility
Vaccines

December 2025

12.18.2025
Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
- Financial
- Finance
12.17.2025
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- Research and Pipeline
- Medicines
12.16.2025
Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
12.12.2025
Pfizer Declares First-Quarter 2026 Dividend
- Financial
- Finance
12.10.2025
TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
- Research and Pipeline
- Medicines
12.09.2025
Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
- Corporate
- Research
12.06.2025
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
- Prescription Medicines
- Medicines
12.01.2025
European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA™ (pembrolizumab) for Certain Patients with Muscle-Invasive Bladder Cancer
- Corporate
- Partnerships
12.01.2025
Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance
- Financial
- Finance

November 2025

11.21.2025
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
- Prescription Medicines
- Medicines
11.13.2025
Pfizer Completes Acquisition of Metsera
- Corporate
- Research and Pipeline
11.12.2025
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Financial
- Finance
11.05.2025
Pfizer Responds to Delaware Chancery Court Ruling
- Corporate
11.04.2025
Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
11.03.2025
Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk
- Corporate

October 2025

10.31.2025
Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement
- Corporate
10.31.2025
Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
- Corporate
10.30.2025
Pfizer Addresses Proposal for Metsera
- Corporate
10.19.2025
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
- Research and Pipeline
- Medicines
10.19.2025
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
- Research and Pipeline
- Medicines
10.18.2025
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
- Research and Pipeline
- Medicines
10.14.2025
TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
- Research and Pipeline
- Medicines
10.13.2025
Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025
10.09.2025
Pfizer Declares Fourth-Quarter 2025 Dividend
- Financial
- Finance

September 2025

09.30.2025
Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
- Corporate
09.25.2025
Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025
- Research and Pipeline
- Research
09.23.2025
Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts
- Financial
- Finance
09.22.2025
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
- Corporate
- Research and Pipeline
09.08.2025
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
- Covid-19
- Vaccines

August 2025

08.27.2025
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
- Covid-19
- Vaccines
08.12.2025
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
- Research and Pipeline
- Medicines
08.05.2025
Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance

July 2025

07.25.2025
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
- Vaccines
- Vaccines
07.24.2025
Pfizer Completes Licensing Agreement with 3SBio
- Corporate
- Research and Pipeline
07.10.2025
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
- Research and Pipeline
- Medicines

June 2025

06.26.2025
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
- Prescription Medicines
- Medicines
06.25.2025
Pfizer Declares Third-Quarter 2025 Dividend
- Financial
- Finance
06.25.2025
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
- Financial
- Finance
06.02.2025
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Financial
- Finance

May 2025

05.31.2025
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
- Research and Pipeline
- Research
05.30.2025
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
- Prescription Medicines
- Medicines
05.22.2025
Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
- Research and Pipeline
- Medicines
05.19.2025
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
- Corporate
- Research and Pipeline

April 2025

04.29.2025
Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
04.26.2025
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
- Research and Pipeline
04.24.2025
Pfizer Announces 2025 Shareholder Meeting Preliminary Results
04.23.2025
Pfizer Declares Second-Quarter 2025 Dividend
- Financial
- Finance
04.23.2025
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
- Research and Pipeline

Current page 1
Page 2
Page 3
Page 4
Page 5

Media Resources & Contact Information

Media Contacts
Press Kits

Anyone may view our press releases, press statements, and press kits.

However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.

Investors
Media
Careers
Partners

PfizerForAll
Healthcare Professionals
Grant Seekers
Business to Business

Privacy Statement
Accessibility Statement
Terms of Use
Contact Us

Glossary

© 2025 Pfizer Inc. All rights reserved

This information—including product information—is intended only for residents of the United States.

The products discussed herein may have different labeling in different countries.

Twitter
Facebook
Linked In
Instagram
Youtube